Journal
BIOMARKERS IN MEDICINE
Volume 7, Issue 6, Pages 867-877Publisher
FUTURE MEDICINE LTD
DOI: 10.2217/bmm.13.104
Keywords
biomarkers; cell-free DNA; circulating nucleic acids; microRNA; miRNA; mRNA; prostate cancer
Categories
Funding
- Cancer Research UK
- Rosetrees Trust
- Prostate Cancer UK
- Martin Harris Research Fellowship
- Prostate Cancer UK [PG10-25] Funding Source: researchfish
Ask authors/readers for more resources
Prostate cancer, the most common cancer of western men, requires new biomarkers, especially given that the benefits of PSA testing remain uncertain. Nucleic acids can now be accurately and sensitively detected in human blood. Over the last decade, investigations into utility of circulating cell-free miRNA, DNA and mRNA as novel biomarkers have expanded exponentially. In the near future, they may be routinely used to accurately diagnose cancers, stratify indolent from aggressive disease and inform treatment decisions. However, advancement of such tests into clinical settings is hampered by technical problems with assay specificity and sensitivity, and small study sizes. This review highlights the different forms of circulating nucleic acids and those that show the most potential as viable biomarkers for prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available